Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.
Bernard J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Camillo Porta
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Bayer; Novartis
Petri Bono
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Expert Testimony - GlaxoSmithKline
Ugo De Giorgi
No relevant relationships to disclose
Omi Parikh
Consultant or Advisory Role - GlaxoSmithKline
Robert E. Hawkins
Consultant or Advisory Role - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline (I)
Honoraria - GlaxoSmithKline
Expert Testimony - GlaxoSmithKline
Emmanuel Sevin
No relevant relationships to disclose
Sylvie Negrier
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - GlaxoSmithKline; Roche
Sadya Khan
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lauren McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Faisal Mehmud
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
David Cella
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline